Generex/Antigen Express "Stock News Now" Interview Available Online

     Generex/Antigen Express "Stock News Now" Interview Available Online

PR Newswire

WORCESTER, Mass. and TORONTO, Feb. 4, 2014

WORCESTER, Mass. and TORONTO, Feb.4, 2014 /PRNewswire/ -- Generex
Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that
an interview of Dr. Eric von Hofe, PhD, President of the Company's
wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com),
conducted by Stock News Now at last month's J.P. Morgan Healthcare Conference
in San Francisco, is now available online. The interview is in respect of the
ongoing Phase II trial of the Antigen Express AE37 breast cancer vaccine.

The interview may be viewed online at:
http://www.youtube.com/watch?v=dmHrOv6DoQo or on the Stock News Now website,
www.stocknewsnow.com.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary
platform technology for the delivery of drugs into the human body through the
oral cavity (with no deposit in the lungs). The Company's proprietary liquid
formulations allow drugs typically administered by injection to be absorbed
into the body by the lining of the inner mouth using the Company's proprietary
RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of
Generex. The core platform technologies of Antigen Express comprise
immunotherapeutic vaccines for the treatment of malignant, infectious,
allergic, and autoimmune diseases. Antigen Express has pioneered the use of
specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses
on modification of peptides with Ii-Key to increase potency, while a second
relies on inhibition of expression of the Ii protein. Antigen Express
scientists, and others, have shown clearly that suppression of expression of
the Ii protein in cancer cells allows for potent stimulation of T-helper cells
and prevents the further growth of cancer cells. For more information, visit
the Generex website at www.generex.comor the Antigen Express website at
www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such as "expects," "plan," "believes," "will," "achieve,"
"anticipate," "would," "should," "subject to" or words of similar meaning, and
by the fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product
applications, potential collaborations, product development activities,
clinical studies, regulatory submissions and approvals, and similar operating
matters. Many factors may cause actual results to differ from forward-looking
statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known
risks and uncertainties include those identified from time to time in the
reports filed by Generex with the Securities and Exchange Commission, which
should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and one
should avoid placing undue reliance on such statements. Generex undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex cannot be sure
when or if it will be permitted by regulatory agencies to undertake additional
clinical trials or to commence any particular phase of clinical trials.
Because of this, statements regarding the expected timing of clinical trials
or ultimate regulatory approval cannot be regarded as actual predictions of
when Generex will obtain regulatory approval for any "phase" of clinical
trials or when it will obtain ultimate regulatory approval by a particular
regulatory agency. Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private Securities
Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

Website: http://www.generex.com
Contact: Todd Falls, Generex Biotechnology Corporation, 800-391-6755
 
Press spacebar to pause and continue. Press esc to stop.